PCR Sample Clauses

PCR. (a) Within ninety (90) days from the date hereof, New Borrower shall commence, and provide Lender with satisfactory evidence of such commencement of, the Immediate Needs described in the PCR (the “Immediate Needs”). If all of such Immediate Needs cannot be completed within said 90-day period despite diligent efforts by New Borrower to achieve the same, then and in such event, the time period to complete any then remaining and outstanding Immediate Needs shall be extended so long as New Borrower continues to use diligent efforts to complete or cause the completion of any such remaining Immediate Repairs, but in no event shall such extended period exceed a period of six (6) months from the date hereof. Upon completion of the Immediate Needs, New Borrower shall pay for a Lender approved inspection company (“Inspector”) to inspect the Project to determine if the Immediate Repairs have been timely and fully completed. If the Immediate Repairs have not been timely and fully completed, the Inspector shall provide a written report regarding the status of the Immediate Needs and shall specifically outline the work necessary to complete the Immediate Needs and a time frame for doing so. New Borrower shall complete the Immediate Needs set forth in the Inspector’s report within the time frame set forth in the Report or New Borrower shall be in default hereunder, whereupon, Lender, in addition to all other rights and remedies for default under the Loan Documents, shall have the right, but not the obligation, to use the funds being held in any of the escrow accounts being held by Lender to complete the Immediate Needs.
AutoNDA by SimpleDocs
PCR. An engineering property condition report by a firm and in a form reasonably acceptable to the Bank, at Borrower’s expense.
PCR. 7.1 The Tenant agrees to pay 50% of the external costs reasonably incurred by the Landlord in preparing the premises condition report (or PCR, as defined in the Lease) which is to be prepared during the Landlord’s due diligence investigations and annexed to the Lease. The Tenant shall make such payment to the Landlord on the date that is 10 Working Days following the later of the Commencement Date and delivery to the Tenant of a valid GST invoice for such sum.
PCR. To establish a profile of the transcriptional changes of the mRNA of specific cytokines and receptors induced by the SNI or and the effect of the investigated drugs on those cytokines, QRT-PCR was performed on tissue of the injured sciatic nerve and spinal cord. Naive mice (n = 5) served as reference for basal mRNA expression levels. Mice that had received SNI, with or without treatment (n = 5/group), were sacrificed 7 days post lesion. The nucleotide sequences of the PCR primers and their fluorogenic probes for the target genes were designed by using the computer program primer express (PE Biosystems) and are included in Table 1. Each fluorescent probe has a reporter dye (FAM for the target RNA and TET for the 18S RNA control) covalently attached at its 5’ end and a quencher dye (XXXXX) attached at its 3’ end. Before use, the probes were purified in the PolyPak II cartridge (Xxxx Research, Sterling, VA) following the manufacturer’s instructions. RNA was isolated from the sciatic nerve Table 1: QRT-PCR primers and probes used in this study. Primers and probes used for the quan- tification of mRNA from NMDA receptor subtypes NR1, NR2A and NR2B (Grin); microglia marker Iba-1 (AIF-1), astrocyte (GFAP) and CCL2; f, Reporter dye1 (FAM:6-carboxyfluorescein); t, Reporter dye 2 (TET:Tetrachloro-6-carboxyfluorescein); q, Quencher dye (XXXXX: 6-carboxytet- ramethyl-1-rhodamine). Gene Type Sequence (5’–3’) Grin1 (NMDAR NR1) Forward GTC CAT CTA CTC TGA CAA GAG Reverse AAA CCA GAC GCT GGA CTG GT Probe f TCC ACC TGA GCT TCC TTC GCA CCGq Grin2a (NMDAR NR2A) Forward ACC TCG CTC TGC TCC AGT TT Reverse GTT GTG GCA GAT GCC CGT AA Probe f CAG TGT CTC CAG CTC TTC CAT CTC ACq Grin2b (NMDAR NR2B) Forward TGG TCT TCT CCA TCA GCA GA Reverse GTT CAT CAC GGA TTG GCG CT Probe f ATC TAC AGC TGT ATC CAC GGA GTA GCq CCL2 Forward CTG GAG CAT CCA CGT GTT G Reverse TGG GAT CAT CTT GCT GGT GA Probe f AGC CAG ATG CAG TTA ACG CCC CAC T q AIF-1 (Iba-1) Forward GCA ATT CCT CGA TGA TCC CA Reverse ATG TAC TTC ACC TTG AAG GCT Probe f CAG CAA TGA TGA GGA TCT GCC GTC CAq GFAP Forward CTC AAG AGG AAC ATC GTG GT Reverse TGC TCC TGC TTC GAG TCC TT Probe f TGA CCT CAC CAT CCC GCA TCT CCAq 18S Forward AGA AAC GGC TAC CAC ATC CA Reverse CTC GAA AGA GTC CTG TAT TGT Probe tAGG CAG CAG GCG CGC AAA TTA Cq and spinal cord from each of 5 mice in the experimental groups outlined above with the ABI Prism 6100 Automated Nucleic Acid Workstation according to the manu- facturer’s protocol. Real-time RT-PCR amplifica...
PCR. The expression of GPR38 mRNA was determined with a semiquantitative RT-PCR; β-actin mRNA expression was used for standardization of the amount of used cDNA. Total RNA from 8 control and 17 IBD (9 CD, 8 UC) mucosal tissue samples was isolated by phenol chloroform extraction of guanidinium isothiocynate lysates [25]. RNA of TE671 cells was used as positive control. With M-MLV reverse transcriptase (Invitrogen, La Jolla, CA, USA) and a random primer mix (Xxxxxxxx- Xx Xxxxx, Switzerland) cDNA was synthesized from 2 µg RNA. The obtained cDNA was serially diluted from 1:4 to 1:1024. The diluted cDNA served as a template for the PCR using REDTaq™ DNA polymerase (Sigma-Xxxxxxx, St. Xxxxx, MO, USA) and primers for GPR38 (forward, CACGTTGGCAGAATCATTTAC; reverse, TCCCATCGTCTTCACGTTAG) or β-actin (forward, GGGTCAGAAG- GATTCCTATG; reverse, GGTCTCAAACATGATCTGGG) (Sigma-Genosys, UK). Following amplification programs were used 1 minute 95°C; 1 minute 53°C; 1 minute 72°C 36 cycles and 30 seconds 94°C; 45 seconds 56°C; 1 minute 72°C 30 cycles for GPR38 and β-actin respectively. PCR fragments were loaded on a 1.5% agarose gel and after electrophoresis DNA was visualized with ethidium bromide under UV light and a digital picture was made. Intensity of the bands was measured with Scion (Washington D.C., USA) imaging software and plotted against starting amount of cDNA on log scale. Ratios of the integrated optical density per μg cDNA between samples and positive control were calculated. Statistics Data is expressed as median values with confidence intervals. For statistical assessment of differences between groups, Xxxxxxxx signed ranks test and a Xxxx-Xxxxxxx U-test were used for paired and unpaired data respectively. Values of P < 0.05 were considered significant. Results Motilin receptors in normal human gastrointestinal tract Quantification of motilin receptor expression With autoradiography the median motilin binding found in the colonic and ileal smooth muscle was 3 and 8 fmol/g tissue, respectively (table 3). This is lower (P < 0.05) than the amount of binding sites present in the human gastroduodenal region (93 fmol/g tissue; range 90-167) which was used as positive control. Besides binding in the muscular compartment, specific motilin binding was found in intestinal mucosa (table 3). In colon and ileum the motilin receptor expression in the mucosa was higher than in the smooth muscle (colon: 11 vs. 3 fmol/g, p≤0.06; ileum: 27 vs. 8 fmol/g, P≤0.05) (table 3), while in ...
PCR. Global and PCRSC desire to contribute and transfer to PSIS and PSIS desires to accept and receive, certain of the assets and assume certain of the liabilities of PCR, Global and PCRSC that are necessary to enable PSIS to own and operate the Business (the "Contribution") and to facilitate the Offering.
PCR. Polymerase chain reactions were set up by using the following reagents multiplied by the number of PCR reactions required (Table 1). For each primer a DNA sample, stored in our R&D approved bio bank, from a positive (known MDR3 deficiency) control was used to check the quality of the designed primer. A negative (no DNA) control mix, with reagents only, was also used to assure the lack of any DNA contamination of the reagents. The PCR plate was covered with an adhesive PCR seal (Anachem, Luton, UK) and the reaction was placed on a thermal cycler with a heated lid at 105 °C as per Table 2. Reagents Volume PCR buffer GC-Rich solution dNTP mix (10 mM) FastStart Taq DNA polymerase (5 U/μl) Forward primer (10 μM) Reverse primer (10 μM) DNA Distilled water 2 μl 4 μl 0.6 μl 0.25 μl 0.5 μl 0.5 μl 2 μl 10.15 μl Total reaction volume 20 μl Table 1: PCR master mix of a total volume of 20 μl. GC; guanine-cytosine. Temperature (oC) Time (min) Number of cycles 96 8 1 96 52-58 72 0.5 0.25 0.5 } 35 72 7 1 Table 2: PCR thermal cycle, with temperatures gradient in step 3 between 52-58 oC, depending on each exon’s annealing temperature.
AutoNDA by SimpleDocs
PCR. After optimizing the annealing temperature and the MgCl2 concentration, micro plates were prepared for the template PCRs for each SNP. A total volume of 1000 μL of PCR mix was prepared for 96 well micro plates for each SNP as following: Table 2.6 PCR mixture for 96 well microplate SNP Sterile water PCR buffer ACGT mix F primer R primer MgCl2 (μl) Red taq polymera (μl) (μl) (μl) (μl) (μl) se (μl) ADIPOQ - 10066 G/A 804.0 100 8.0 4.0 4.0 60.0 20.0 ADIPOQ - 7734 C/A 784.0 100 8.0 4.0 4.0 80.0 20.0 ADIPOQ - 11391 G/A 784.0 100 8.0 4.0 4.0 80.0 20.0 ADIPOQ + 276 G/T 804.0 100 8.0 4.0 4.0 60.0 20.0 PPARA Leu162Val 804.0 100 8.0 4.0 4.0 60.0 20.0 Into each well of the PCR plate, 10 μl of PCR mix was pipetted. This was followed by pipating 1.5 μl of the DNA sample into the appropriate well. The plate was then covered and placed into Tetrad Thermocycler and programmed for the specific conditions required for the SNP. Table 2.7 PCR conditions for the selected SNPs SNP PCR cycling conditions ADIPOQ -10066 G/A and -7734 C/A ADIPOQ -11391 G/A and + 276 G/T 1 cycle at 94 °C for 6 minutes; 50 cycles at 94°C for 1 minute; 61 °C for 30 seconds; 72°C for 30 seconds; 1 cycle at 72°C for 10 minutes. 1 cycle at 94 °C for 6 minutes; 50 cycles at 94°C for 1 minute; 59 °C for PPARA Leu162Val 1 cycle at 94 °C for 6 minutes; 50 cycles at 94°C for 1 minute; 54.0 °C for 45 seconds; 72°C for 1 minutes ; 1 cycle at 72°C for 10 minutes. The completed PCR was the removed and stored in a 40C fridge ready for the Pyrosequencer.

Related to PCR

  • Design At no cost to SCE, Seller shall be responsible for:

  • Raw Materials Lonza shall procure all required Raw Materials as well as consumables other than those Raw Materials that are Customer Materials. Customer shall be responsible for payment for all consumables and Raw Materials ordered or irrevocably committed to be procured by Lonza hereunder. Upon cancellation of any Batch or termination of the Agreement, all unused Raw Materials shall be paid for by Customer within [***] days of invoice and at Customer’s option will either be (a) held by Lonza for future use for the production of Product, (b) delivered to Customer, or (c) disposed of by Lonza.

  • Project Scope The physical scope of the Project shall be limited to only those capital improvements as described in Appendix A of this Agreement. In the event that circumstances require a change in such physical scope, the change must be approved by the District Committee, recorded in the District Committee's official meeting minutes, and provided to the OPWC Director for the execution of an amendment to this Agreement.

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • New Technology When new or updated technology is introduced into a workplace, it will be the responsibility of the employer to provide appropriate and, if necessary, ongoing training to the employees directly affected. Such training will include any health and safety implications or information that will enable employees to operate the equipment without discomfort and will help maintain their general well-being.

  • Quality All products will be new and unused. All products provided by the Contractor must meet all federal, state, and local standards for quality and safety requirements. Products not meeting the requirements of this section will be deemed unacceptable and returned to the Contractor for credit at no charge to the State.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • USE OF THIRD PARTY SYSTEMS-LEVEL SOFTWARE State Street and the Fund acknowledge that in connection with the Data Access Services provided under this Addendum, the Fund will have access, through the Data Access Services, to Fund Data and to functions of State Street’s proprietary systems; provided, however that in no event will the Fund have direct access to any third party systems-level software that retrieves data for, stores data from, or otherwise supports the System.

  • Technical Specifications The Technical Specifications furnished on the CD are intended to establish the standards for quality, performance and technical requirements for all labor, workmanship, material, methods and equipment necessary to complete the Work. When specifications and drawings are provided or referenced by the County, these are to be considered part of the Scope of Work, and to be specifically documented in the Detailed Scope of Work. For convenience, the County supplied specifications, if any, and the Technical Specifications furnished on the CD.

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!